Literature DB >> 17062702

Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.

Allan Lipton1, James R Berenson, Jean-Jacques Body, Brendan F Boyce, Oyvind S Bruland, Michael A Carducci, Charles S Cleeland, Denis R Clohisy, Robert E Coleman, Richard J Cook, Theresa A Guise, Roger N Pearse, Trevor J Powles, Michael J Rogers, G David Roodman, Matthew R Smith, Larry J Suva, Robert L Vessella, Katherine N Weilbaecher, Laura King.   

Abstract

The First Cambridge Conference on Advances in Treating Metastatic Bone Cancer, a symposium held in Cambridge, Massachusetts, October 28 to 29, 2005, was convened to discuss recent advances and research related to the natural history of bone metastases and skeletal complications, bone cancer biology, treatment of myeloma and other solid tumors, and treatment-induced bone loss. The conference format combined brief presentations with extended periods of discussion. The conclusions reached during the 2-day meeting are summarized in this article and presented in more detail in the individual articles and accompanying discussion sessions that comprise the conference proceedings.

Entities:  

Mesh:

Year:  2006        PMID: 17062702      PMCID: PMC2705325          DOI: 10.1158/1078-0432.CCR-06-1213

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.

Authors:  Manali S Bendre; Aaron G Margulies; Brandon Walser; Nisreen S Akel; Sudeepa Bhattacharrya; Robert A Skinner; Frances Swain; Vishnu Ramani; Khalid S Mohammad; Lisa L Wessner; Alfredo Martinez; Theresa A Guise; John M Chirgwin; Dana Gaddy; Larry J Suva
Journal:  Cancer Res       Date:  2005-12-01       Impact factor: 12.701

2.  Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway.

Authors:  Yibin Kang; Wei He; Shaun Tulley; Gaorav P Gupta; Inna Serganova; Chang-Rung Chen; Katia Manova-Todorova; Ronald Blasberg; William L Gerald; Joan Massagué
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-19       Impact factor: 11.205

3.  First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.

Authors:  Sten Nilsson; Roy H Larsen; Sophie D Fosså; Lise Balteskard; Kari W Borch; Jan-Erik Westlin; Gro Salberg; Oyvind S Bruland
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

Review 4.  Bisphosphonates in the treatment of metastatic breast cancer.

Authors:  J J Body
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

5.  Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.

Authors:  Sarah L Dallas; Jennifer L Rosser; Gregory R Mundy; Lynda F Bonewald
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

Review 6.  The diagnosis and treatment of osteoporosis in men on androgen deprivation therapy for advanced carcinoma of the prostate.

Authors:  David C Bae; Barry S Stein
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

7.  Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways.

Authors:  Sanna-Maria Kakonen; Katri S Selander; John M Chirgwin; Juan Juan Yin; Suzanne Burns; Wayne A Rankin; Barry G Grubbs; Mark Dallas; Yong Cui; Theresa A Guise
Journal:  J Biol Chem       Date:  2002-04-18       Impact factor: 5.157

Review 8.  Osteoporosis during androgen deprivation therapy for prostate cancer.

Authors:  Matthew R Smith
Journal:  Urology       Date:  2002-09       Impact factor: 2.649

9.  A multigenic program mediating breast cancer metastasis to bone.

Authors:  Yibin Kang; Peter M Siegel; Weiping Shu; Maria Drobnjak; Sanna M Kakonen; Carlos Cordón-Cardo; Theresa A Guise; Joan Massagué
Journal:  Cancer Cell       Date:  2003-06       Impact factor: 31.743

10.  The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.

Authors:  Isaiah J Fidler
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

View more
  5 in total

1.  A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.

Authors:  Monica M Reinholz; Shawn P Zinnen; Amylou C Dueck; David Dingli; Gregory G Reinholz; Leslie A Jonart; Kathleen A Kitzmann; Amy K Bruzek; Vivian Negron; Abdalla K Abdalla; Bonnie K Arendt; Anthony J Croatt; Luis Sanchez-Perez; David P Sebesta; Harri Lönnberg; Toshiyuki Yoneda; Karl A Nath; Diane F Jelinek; Stephen J Russell; James N Ingle; Thomas C Spelsberg; Henry B F Hal Dixon; Alexander Karpeisky; Wilma L Lingle
Journal:  Bone       Date:  2010-03-15       Impact factor: 4.398

2.  Bioluminescence and near-infrared fluorescence imaging for detection of metastatic bone tumors.

Authors:  Wonbong Lim; Bora Kim; Gayoung Jo; Dae Hyeok Yang; Min Ho Park; Hoon Hyun
Journal:  Lasers Med Sci       Date:  2019-06-01       Impact factor: 3.161

Review 3.  The best of both worlds - managing the cancer, saving the bone.

Authors:  Issam Makhoul; Corey O Montgomery; Dana Gaddy; Larry J Suva
Journal:  Nat Rev Endocrinol       Date:  2015-10-27       Impact factor: 43.330

Review 4.  The role of the bone microenvironment in skeletal metastasis.

Authors:  Yu Zheng; Hong Zhou; Colin R Dunstan; Robert L Sutherland; Markus J Seibel
Journal:  J Bone Oncol       Date:  2012-12-11       Impact factor: 4.072

5.  Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.

Authors:  Jin Liu; Defang Li; Lei Dang; Chao Liang; Baosheng Guo; Cheng Lu; Xiaojuan He; Hilda Y S Cheung; Bing He; Biao Liu; Fangfei Li; Jun Lu; Luyao Wang; Atik Badshah Shaikh; Feng Jiang; Changwei Lu; Songlin Peng; Zongkang Zhang; Bao-Ting Zhang; Xiaohua Pan; Lianbo Xiao; Aiping Lu; Ge Zhang
Journal:  Sci Rep       Date:  2017-01-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.